Overview

A Study to Assess the Effects of DPP-4 Inhibition on Insulin Sensitivity in Type 2 Diabetes

Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
Type 2 diabetes results when the body does not produce enough insulin and/or is unable to properly use the insulin it makes (insulin resistance). This study was undertaken to assess the effects of vildagliptin on insulin sensitivity in people with type 2 diabetes.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Insulin
Insulin, Globin Zinc
Vildagliptin